Form 4: Immunocore Director Kristine Peterson Receives Option Grant

Director Kristine Peterson was granted 27,492 stock options in Immunocore Holdings plc as part of a standard equity incentive.

Summary

• Director Kristine Peterson received an option grant for 27,492 ordinary shares of Immunocore Holdings plc.
• The options have an exercise price of $28.52 per share.
• The grant date for the transaction was May 27, 2026.
• The options are set to expire on May 26, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying shares relative to the $28.52 exercise price.

Future Outlook

The options vest on the earlier of May 27, 2027, or the day prior to the next annual general meeting, contingent on continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to attract and retain board expertise, aligning leadership with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The use of time-based vesting is a common industry benchmark for director compensation.

Stakeholder Impact

• Minor dilution impact for shareholders upon future exercise of options.

Next Steps

• Vesting of options on May 27, 2027, or the day prior to the next annual general meeting.

Key Dates

Keywords

Immunocore, IMCR, Director Compensation, Stock Options, Insider Transaction, Biotech